ARMP — Armata Pharmaceuticals, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 921114 ·
Last close
$7.06
Market Cap
$259.18M
52W High
$14.98
52W Low
$6.37
ADV30
68,538
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -8,785,000 | -115,346,000 | 69,800,000 | 4,754,000 | 381,386,000 |
| Dec 2025 | 0 | — | -8,411,000 | -124,298,000 | 76,882,000 | 8,688,000 | 295,478,000 |
| Sep 2025 | 0 | — | -7,776,000 | -26,675,000 | 89,516,000 | 14,756,000 | 185,104,000 |
| Jun 2025 | 0 | — | -6,844,000 | -16,295,000 | 80,790,000 | 4,328,000 | 150,293,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,965,000
Investing CF
$-506,000
Financing CF
$16,267,000
CapEx
$-506,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.55
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-616,880,000
Inventory
—
Receivables
$47,000
ST Investments
—
EBIT TTM
$-264,067,000
Pretax Income TTM
$-282,614,000
Interest Exp TTM
$18,547,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,202,000
EBITDA
$-30,205,000
Free Cash Flow
$-26,138,876
Enterprise Value
$617,737,536
Total Cash
$4,754,000
Total Debt
$373,673,984
Shares Out
36,710,810
Trailing EPS
$-7.78
Book Value
$-8.50
ROE
—
ROA
-25.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -31,222,000 | -173,799,000 | 76,882,000 | 295,478,000 | — | -25,763,000 |
| Dec 2024 | 0 | -42,436,000 | -18,916,000 | 86,437,000 | 134,456,000 | — | -37,551,000 |
| Dec 2023 | 0 | -40,890,000 | -69,045,000 | 98,363,000 | 130,428,000 | — | -47,423,000 |
| Dec 2022 | 0 | -36,946,000 | -36,917,000 | 95,834,000 | 59,754,000 | — | -32,481,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.57
Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $7.06 · call volume: 12 · put volume: 1Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HUMA | Humacyte, Inc. | $261.25M | $0.97 | — |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $247.43M | $2.67 | — |
| IVVD | Invivyd, Inc. | $274.34M | $0.93 | — |
| SRZN | Surrozen, Inc./DE | $279.11M | $24.04 | — |
| NMRA | Neumora Therapeutics, Inc. | $283.48M | $1.53 | — |
News headlines (Yahoo Finance, 1h cache)
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
2026-05-13 20:30 · Yahoo
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
2026-05-07 11:00 · Yahoo
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
2026-05-04 11:00 · Yahoo
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
2026-04-27 11:00 · Yahoo
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
2026-03-25 20:05 · Yahoo
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
2026-03-19 11:00 · Yahoo
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod
2026-03-02 15:23 · Yahoo
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
2026-02-23 12:00 · Yahoo
/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./
2026-01-13 12:42 · Yahoo
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
2025-11-18 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.